In an evolving healthcare landscape, the Alpha Mannosidosis market stands at a pivotal juncture, promising substantial advancements in treatment options. As of 2024, the market is projected to reach USD 15.02 million, with expectations of climbing to USD 33.97 million by 2035, reflecting a compound annual growth rate (CAGR) of 7.70%. This anticipated growth is fueled by increasing awareness of...